Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
ADCs offer a promising avenue for NSCLC treatment. Nonetheless, the risk of D-ILD necessitates a balanced approach in ADC development, focusing on optimizing linker and payload properties to mitigate this adverse effect. Further research is essential to better understand and manage D-ILD, ensuring the safe and effective use of ADCs in clinical practice.
Authors
- Sinchita Roy‐Chowdhuri (ORCID: https://orcid.org/0000-0002-9447-7701)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Solange Peters (ORCID: https://orcid.org/0000-0002-0412-7143)
- Ajay Sheshadri (ORCID: https://orcid.org/0000-0002-8091-0180)
- Aakash Desai (ORCID: https://orcid.org/0000-0002-2943-3817)
- Sameer Deshmukh (ORCID: https://orcid.org/0000-0002-6762-1317)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Alabama at Birmingham (US)
- Sarah Cannon (US)
- University of Lausanne (CH)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-07
- DOI
- https://doi.org/10.3390/cancers16223753
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70